ICON Public Key Executives
This section highlights ICON Public's key executives, including their titles and compensation details.
Find Contacts at ICON Public
(Showing 0 of )
ICON Public Earnings
This section highlights ICON Public's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|---|---|---|---|---|
| Read Transcript | Q4 | 2024 | 2025-02-20 | N/A | N/A |
| Read Transcript | Q3 | 2024 | 2024-10-24 | N/A | N/A |
| Read Transcript | Q2 | 2024 | 2024-07-25 | N/A | N/A |
| Read Transcript | Q1 | 2024 | 2024-04-25 | N/A | N/A |
| Read Transcript | Q4 | 2023 | 2024-02-22 | N/A | N/A |
| Read Transcript | Q3 | 2023 | 2023-10-26 | N/A | N/A |
| Read Transcript | Q2 | 2023 | 2023-07-27 | N/A | N/A |
| Read Transcript | Q1 | 2023 | 2023-04-27 | N/A | N/A |
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It offers clinical development services, including early development, patient recruitment and retention, strategy and analytics, late phase research, data and technology solution, and consulting and analytics services. The company's clinical development services also comprise medical imaging, clinical research and laboratory services, project management, site monitoring and management services, data management, biostatistics and programming, medical writing and publishing, medical affair, endpoint adjudication/data monitoring committees, pharmacovigilance, interactive response technologies, clinical supplies management, strategic regulatory, medical communication, and consulting and advisory services. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company was incorporated in 1990 and is headquartered in Dublin, Ireland.
$184.87
Stock Price
$14.93B
Market Cap
41.90K
Employees
Dublin, None
Location
Financial Statements
Access annual & quarterly financial statements for ICON Public, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $8.28B | $8.12B | $7.74B | $5.48B | $2.80B |
| Cost of Revenue | $5.85B | $5.72B | $5.53B | $3.97B | $1.99B |
| Gross Profit | $2.44B | $2.40B | $2.21B | $1.51B | $808.03M |
| Gross Profit Ratio | 29.42% | 29.60% | 28.60% | 27.50% | 28.89% |
| Research and Development Expenses | $- | $- | $- | $- | $- |
| General and Administrative Expenses | $- | $- | $- | $- | $- |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $728.35M | $776.36M | $778.75M | $585.33M | $341.69M |
| Other Expenses | $610.20M | $667.72M | $569.51M | $314.99M | $74.38M |
| Operating Expenses | $1.34B | $1.44B | $1.35B | $900.32M | $416.06M |
| Cost and Expenses | $7.18B | $7.16B | $6.88B | $4.87B | $2.41B |
| Interest Income | $8.61M | $5.01M | $2.35M | $574.00K | $2.72M |
| Interest Expense | $237.24M | $336.70M | $229.73M | $182.42M | $15.07M |
| Depreciation and Amortization | $488.50M | $585.95M | $614.73M | $360.33M | $94.61M |
| EBITDA | $1.59B | $1.52B | $1.41B | $739.43M | $488.83M |
| EBITDA Ratio | 19.26% | 18.74% | 18.57% | 16.85% | 17.48% |
| Operating Income | $1.10B | $956.15M | $795.24M | $608.47M | $391.97M |
| Operating Income Ratio | 13.26% | 11.78% | 10.27% | 11.10% | 14.01% |
| Total Other Income Expenses Net | $-228.63M | $-331.69M | $-227.39M | $-181.85M | $-10.29M |
| Income Before Tax | $869.18M | $624.47M | $567.85M | $196.68M | $382.18M |
| Income Before Tax Ratio | 10.50% | 7.69% | 7.34% | 3.59% | 13.66% |
| Income Tax Expense | $77.71M | $11.75M | $59.41M | $41.33M | $50.75M |
| Net Income | $791.47M | $612.34M | $505.30M | $153.19M | $327.81M |
| Net Income Ratio | 9.56% | 7.54% | 6.53% | 2.79% | 11.72% |
| EPS | $9.60 | $7.46 | $6.20 | $2.28 | $6.29 |
| EPS Diluted | $9.53 | $7.40 | $6.13 | $2.25 | $6.24 |
| Weighted Average Shares Outstanding | 82.48M | 82.10M | 81.53M | 67.11M | 52.86M |
| Weighted Average Shares Outstanding Diluted | 83.03M | 82.72M | 82.47M | 68.07M | 53.28M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.04B | $2.03B | $2.12B | $2.09B | $2.07B | $2.06B | $2.02B | $1.98B | $1.96B | $1.94B | $1.94B | $1.90B | $1.89B | $1.87B | $871.15M | $858.20M | $760.23M | $701.73M | $620.23M | $715.10M |
| Cost of Revenue | $1.44B | $1.44B | $1.64B | $1.62B | $1.60B | $1.45B | $1.43B | $1.40B | $1.38B | $1.38B | $1.39B | $1.38B | $1.36B | $1.36B | $631.12M | $626.24M | $535.35M | $493.41M | $445.83M | $505.29M |
| Gross Profit | $599.37M | $591.41M | $476.92M | $469.84M | $470.79M | $605.96M | $590.71M | $583.03M | $581.32M | $566.59M | $543.13M | $523.30M | $527.82M | $508.41M | $240.03M | $231.95M | $224.88M | $208.32M | $174.40M | $209.81M |
| Gross Profit Ratio | 29.36% | 29.10% | 22.50% | 22.50% | 22.80% | 29.50% | 29.20% | 29.50% | 29.60% | 29.20% | 28.10% | 27.50% | 28.00% | 27.20% | 27.60% | 27.00% | 29.58% | 29.69% | 28.12% | 29.34% |
| Research and Development Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| General and Administrative Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $151.44M | $205.09M | $194.46M | $177.35M | $195.56M | $185.19M | $187.81M | $200.01M | $226.75M | $166.79M | $189.95M | $195.26M | $202.72M | $206.71M | $109.88M | $98.53M | $87.88M | $83.12M | $83.50M | $87.20M |
| Other Expenses | $150.90M | $100.89M | $202.24M | $- | $- | $- | $- | $145.13M | $142.23M | $141.86M | $144.02M | $141.41M | $139.67M | $140.64M | $17.28M | $17.41M | $17.14M | $16.80M | $15.86M | $16.32M |
| Operating Expenses | $302.34M | $305.98M | $194.46M | $177.35M | $195.56M | $331.22M | $332.87M | $345.13M | $368.98M | $308.65M | $333.97M | $336.67M | $342.39M | $347.35M | $127.16M | $115.94M | $105.02M | $99.92M | $99.36M | $103.52M |
| Cost and Expenses | $1.74B | $1.74B | $1.84B | $1.80B | $1.79B | $1.78B | $1.76B | $1.74B | $1.75B | $1.68B | $1.73B | $1.72B | $1.70B | $1.71B | $758.28M | $742.18M | $640.37M | $593.33M | $545.19M | $608.81M |
| Interest Income | $3.01M | $2.43M | $1.24M | $1.93M | $1.72M | $1.27M | $949.00K | $1.07M | $618.00K | $1.43M | $166.00K | $127.00K | $78.00K | $53.00K | $186.00K | $257.00K | $206.00K | $268.00K | $441.00K | $1.81M |
| Interest Expense | $51.43M | $53.30M | $60.84M | $71.67M | $81.03M | $83.91M | $85.21M | $86.55M | $75.19M | $63.01M | $47.11M | $44.42M | $52.84M | $102.31M | $24.55M | $2.47M | $3.17M | $3.24M | $3.22M | $3.18M |
| Depreciation and Amortization | $96.66M | $93.03M | $157.53M | $160.65M | $157.30M | $156.40M | $157.36M | $156.43M | $152.21M | $141.86M | $144.02M | $141.41M | $154.40M | $157.21M | $24.20M | $24.52M | $17.14M | $16.80M | $15.86M | $16.32M |
| EBITDA | $365.65M | $380.90M | $440.00M | $453.14M | $424.59M | $421.99M | $367.80M | $374.29M | $356.19M | $399.80M | $353.18M | $328.04M | $299.01M | $162.37M | $137.26M | $140.79M | $136.74M | $125.47M | $90.90M | $124.42M |
| EBITDA Ratio | 17.91% | 18.76% | 20.75% | 21.68% | 20.93% | 20.54% | 19.99% | 19.41% | 18.10% | 20.66% | 18.26% | 17.26% | 17.25% | 16.17% | 14.96% | 15.55% | 18.02% | 17.88% | 14.73% | 17.40% |
| Operating Income | $297.02M | $285.43M | $282.47M | $292.49M | $275.23M | $264.31M | $209.48M | $216.79M | $203.36M | $243.74M | $177.79M | $170.34M | $144.53M | $5.11M | $112.87M | $116.01M | $119.86M | $108.40M | $56.95M | $106.29M |
| Operating Income Ratio | 14.55% | 14.06% | 13.32% | 13.99% | 13.32% | 12.86% | 10.37% | 10.96% | 10.37% | 12.55% | 9.19% | 8.96% | 7.67% | 0.27% | 12.96% | 13.52% | 15.77% | 15.45% | 9.18% | 14.86% |
| Total Other Income Expenses Net | $-48.42M | $-50.87M | $-59.60M | $-69.73M | $-79.31M | $-82.64M | $-84.26M | $-85.48M | $-74.57M | $-61.58M | $-46.95M | $-44.30M | $-52.76M | $-102.25M | $-24.36M | $-2.47M | $-3.17M | $-2.97M | $-2.78M | $-1.37M |
| Income Before Tax | $248.60M | $234.56M | $170.25M | $215.76M | $186.25M | $181.68M | $125.23M | $131.31M | $128.80M | $182.17M | $130.84M | $126.04M | $91.77M | $-97.14M | $88.51M | $113.54M | $116.69M | $105.43M | $54.17M | $104.92M |
| Income Before Tax Ratio | 12.18% | 11.55% | 8.03% | 10.32% | 9.01% | 8.84% | 6.20% | 6.64% | 6.56% | 9.38% | 6.76% | 6.63% | 4.87% | -5.21% | 10.16% | 13.23% | 15.35% | 15.02% | 8.73% | 14.67% |
| Income Tax Expense | $-11.39M | $37.44M | $23.34M | $28.32M | $-30.16M | $18.01M | $9.63M | $14.27M | $10.86M | $21.01M | $14.25M | $13.29M | $14.62M | $-3.56M | $14.13M | $16.15M | $15.17M | $13.71M | $6.41M | $12.59M |
| Net Income | $260.00M | $197.13M | $146.91M | $187.44M | $216.42M | $163.66M | $115.60M | $116.65M | $117.44M | $160.15M | $115.73M | $111.97M | $76.47M | $-94.27M | $73.86M | $97.12M | $101.23M | $91.64M | $47.76M | $91.70M |
| Net Income Ratio | 12.74% | 9.71% | 6.93% | 8.97% | 10.47% | 7.96% | 5.72% | 5.90% | 5.99% | 8.25% | 5.98% | 5.89% | 4.06% | -5.05% | 8.48% | 11.32% | 13.32% | 13.06% | 7.70% | 12.82% |
| EPS | $3.18 | $2.38 | $1.78 | $2.27 | $2.63 | $1.99 | $1.41 | $1.43 | $1.44 | $1.96 | $1.42 | $1.37 | $0.94 | $-1.17 | $1.40 | $1.84 | $1.92 | $1.74 | $0.91 | $1.63 |
| EPS Diluted | $3.16 | $2.36 | $1.76 | $2.25 | $2.60 | $1.97 | $1.40 | $1.41 | $1.42 | $1.94 | $1.41 | $1.36 | $0.92 | $-1.17 | $1.38 | $1.82 | $1.90 | $1.72 | $0.90 | $1.62 |
| Weighted Average Shares Outstanding | 81.79M | 82.83M | 82.74M | 82.58M | 82.40M | 82.22M | 82.00M | 81.78M | 81.68M | 81.58M | 81.40M | 81.46M | 81.49M | 80.57M | 52.91M | 52.81M | 52.78M | 52.74M | 52.57M | 53.35M |
| Weighted Average Shares Outstanding Diluted | 82.24M | 83.45M | 83.36M | 83.25M | 83.11M | 82.97M | 82.63M | 82.61M | 82.45M | 82.49M | 82.31M | 82.61M | 82.83M | 80.77M | 53.38M | 53.31M | 53.29M | 53.19M | 53.03M | 53.91M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $538.78M | $378.10M | $288.77M | $752.21M | $840.30M |
| Short Term Investments | $- | $1.95M | $1.71M | $1.71M | $1.73M |
| Cash and Short Term Investments | $538.78M | $380.06M | $290.48M | $753.92M | $842.03M |
| Net Receivables | $2.69B | $2.90B | $2.80B | $2.07B | $1.14B |
| Inventory | $- | $- | $7.06M | $1 | $4.81M |
| Other Current Assets | $303.44M | $132.10M | $137.09M | $114.32M | $116.99M |
| Total Current Assets | $3.53B | $3.41B | $3.23B | $2.94B | $2.11B |
| Property Plant Equipment Net | $530.48M | $501.52M | $504.15M | $534.57M | $192.91M |
| Goodwill | $9.05B | $9.02B | $8.97B | $9.04B | $936.26M |
| Intangible Assets | $3.56B | $3.86B | $4.28B | $4.71B | $66.46M |
| Goodwill and Intangible Assets | $12.61B | $12.88B | $13.25B | $13.75B | $1.08B |
| Long Term Investments | $57.95M | $46.80M | $32.63M | $24.96M | $20.30M |
| Tax Assets | $74.76M | $73.66M | $76.93M | $48.39M | $30.37M |
| Other Non-Current Assets | $72.80M | $78.47M | $92.17M | $89.19M | $26.90M |
| Total Non-Current Assets | $13.35B | $13.58B | $13.96B | $14.45B | $1.35B |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $16.88B | $16.99B | $17.19B | $17.39B | $3.47B |
| Account Payables | $173.03M | $131.58M | $81.19M | $90.76M | $51.11M |
| Short Term Debt | $29.76M | $146.56M | $98.81M | $105.10M | $-498.35M |
| Tax Payables | $55.26M | $13.97M | $41.78M | $59.43M | $26.72M |
| Deferred Revenue | $- | $1.65B | $1.51B | $1.32B | $660.93M |
| Other Current Liabilities | $2.54B | $878.99M | $961.37M | $899.68M | $360.90M |
| Total Current Liabilities | $2.80B | $2.83B | $2.69B | $2.48B | $1.14B |
| Long Term Debt | $3.54B | $3.79B | $4.73B | $5.54B | $409.28M |
| Deferred Revenue Non-Current | $- | $- | $- | $735.00K | $838.00K |
| Deferred Tax Liabilities Non-Current | $812.49M | $899.10M | $988.59M | $1.09B | $10.17M |
| Other Non-Current Liabilities | $209.30M | $232.65M | $277.45M | $213.97M | $36.53M |
| Total Non-Current Liabilities | $4.56B | $4.92B | $6.00B | $6.84B | $446.65M |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $7.35B | $7.75B | $8.69B | $9.32B | $1.59B |
| Preferred Stock | $- | $- | $- | $- | $- |
| Common Stock | $6.59M | $6.70M | $6.65M | $6.64M | $4.58M |
| Retained Earnings | $2.72B | $2.43B | $1.82B | $1.42B | $1.39B |
| Accumulated Other Comprehensive Income Loss | $-228.62M | $-142.34M | $-171.54M | $-90.94M | $-13.00M |
| Other Total Stockholders Equity | $7.02B | $6.94B | $6.84B | $6.73B | $617.10M |
| Total Stockholders Equity | $9.52B | $9.24B | $8.50B | $8.07B | $1.88B |
| Total Equity | $9.52B | $9.24B | $8.50B | $8.07B | $1.88B |
| Total Liabilities and Stockholders Equity | $16.88B | $16.99B | $17.19B | $17.39B | $3.47B |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $16.88B | $16.99B | $17.19B | $17.39B | $3.47B |
| Total Investments | $57.95M | $48.76M | $34.34M | $26.68M | $22.03M |
| Total Debt | $3.57B | $3.94B | $4.79B | $5.60B | $433.61M |
| Net Debt | $3.03B | $3.56B | $4.50B | $4.84B | $-406.69M |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $538.78M | $695.51M | $506.55M | $396.08M | $378.10M | $313.06M | $270.18M | $279.88M | $288.77M | $609.16M | $614.92M | $559.10M | $752.21M | $1.01B | $1.06B | $942.46M | $840.30M | $708.00M | $592.10M | $482.37M |
| Short Term Investments | $- | $- | $- | $1.96M | $1.95M | $1.95M | $1.65M | $1.65M | $1.71M | $1.71M | $1.71M | $1.71M | $1.71M | $1.71M | $1.73M | $1.73M | $1.73M | $1.73M | $1.73M | $1.73M |
| Cash and Short Term Investments | $538.78M | $695.51M | $506.55M | $398.04M | $380.06M | $315.02M | $271.83M | $281.53M | $290.48M | $610.87M | $616.63M | $560.81M | $753.92M | $1.01B | $1.06B | $944.18M | $842.03M | $709.72M | $593.83M | $484.10M |
| Net Receivables | $2.69B | $2.94B | $2.96B | $3.01B | $2.90B | $2.96B | $2.94B | $2.98B | $2.80B | $2.43B | $2.18B | $2.16B | $2.07B | $1.99B | $1.16B | $1.14B | $1.14B | $1.02B | $946.46M | $1.03B |
| Inventory | $- | $- | $1 | $-2.90M | $1 | $1 | $- | $- | $7.06M | $- | $- | $- | $1 | $- | $2 | $- | $4.81M | $- | $1 | $1 |
| Other Current Assets | $303.44M | $140.54M | $139.24M | $149.13M | $132.10M | $150.19M | $152.77M | $170.17M | $137.09M | $129.22M | $130.98M | $151.14M | $114.32M | $131.55M | $71.20M | $87.27M | $116.99M | $42.95M | $38.11M | $41.98M |
| Total Current Assets | $3.53B | $3.78B | $3.60B | $3.55B | $3.41B | $3.42B | $3.37B | $3.43B | $3.23B | $3.17B | $2.93B | $2.87B | $2.94B | $3.13B | $2.29B | $2.17B | $2.11B | $1.77B | $1.58B | $1.56B |
| Property Plant Equipment Net | $530.48M | $522.68M | $503.63M | $512.92M | $501.52M | $474.58M | $491.04M | $498.60M | $504.15M | $452.52M | $473.53M | $509.84M | $534.57M | $557.56M | $235.48M | $240.38M | $192.91M | $245.73M | $248.82M | $262.09M |
| Goodwill | $9.05B | $9.09B | $9.02B | $9.02B | $9.02B | $8.98B | $8.99B | $8.98B | $8.97B | $8.94B | $8.97B | $9.03B | $9.04B | $8.94B | $933.39M | $927.74M | $936.26M | $914.41M | $901.25M | $893.03M |
| Intangible Assets | $3.56B | $3.61B | $3.63B | $3.75B | $3.86B | $3.93B | $4.05B | $4.16B | $4.28B | $4.39B | $4.51B | $4.59B | $4.71B | $4.82B | $57.07M | $60.60M | $66.46M | $69.37M | $72.75M | $78.66M |
| Goodwill and Intangible Assets | $12.61B | $12.69B | $12.65B | $12.77B | $12.88B | $12.92B | $13.04B | $13.14B | $13.25B | $13.33B | $13.48B | $13.62B | $13.75B | $13.75B | $990.46M | $988.34M | $1.08B | $983.78M | $973.99M | $971.70M |
| Long Term Investments | $57.95M | $53.72M | $137.83M | $138.36M | $46.80M | $41.79M | $35.30M | $32.05M | $32.63M | $27.93M | $27.62M | $27.58M | $24.96M | $25.82M | $26.04M | $22.87M | $20.30M | $17.81M | $11.33M | $10.04M |
| Tax Assets | $74.76M | $75.99M | $74.79M | $74.78M | $73.66M | $83.09M | $80.77M | $89.41M | $76.93M | $62.30M | $54.05M | $54.36M | $48.39M | $117.31M | $12.28M | $12.55M | $30.37M | $14.18M | $15.79M | $14.93M |
| Other Non-Current Assets | $72.80M | $88.44M | $- | $- | $78.47M | $93.28M | $89.31M | $93.69M | $92.17M | $77.26M | $72.07M | $80.15M | $89.19M | $73.76M | $34.82M | $33.36M | $26.90M | $32.74M | $30.39M | $27.02M |
| Total Non-Current Assets | $13.35B | $13.43B | $13.37B | $13.49B | $13.58B | $13.61B | $13.74B | $13.86B | $13.96B | $13.95B | $14.11B | $14.29B | $14.45B | $14.52B | $1.30B | $1.30B | $1.35B | $1.29B | $1.28B | $1.29B |
| Other Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $16.88B | $17.21B | $16.97B | $17.05B | $16.99B | $17.03B | $17.11B | $17.29B | $17.19B | $17.13B | $17.04B | $17.16B | $17.39B | $17.65B | $3.58B | $3.47B | $3.47B | $3.07B | $2.86B | $2.84B |
| Account Payables | $173.03M | $106.17M | $83.04M | $113.58M | $131.58M | $87.32M | $46.92M | $85.13M | $81.19M | $60.85M | $77.65M | $63.51M | $90.76M | $62.58M | $37.82M | $48.10M | $51.11M | $28.70M | $32.72M | $23.33M |
| Short Term Debt | $29.76M | $29.76M | $29.76M | $79.76M | $146.56M | $130.15M | $105.15M | $135.15M | $98.81M | $55.15M | $55.15M | $55.15M | $105.10M | $117.05M | $- | $- | $-498.35M | $349.92M | $349.83M | $349.73M |
| Tax Payables | $55.26M | $52.59M | $27.93M | $41.91M | $13.97M | $41.52M | $39.88M | $68.68M | $41.78M | $72.58M | $38.22M | $40.64M | $59.43M | $39.61M | $9.40M | $16.67M | $26.72M | $11.51M | $9.19M | $14.06M |
| Deferred Revenue | $- | $1.59B | $1.60B | $1.71B | $1.65B | $1.66B | $1.57B | $1.58B | $1.51B | $1.40B | $1.19B | $1.30B | $1.32B | $1.35B | $675.23M | $610.48M | $660.93M | $450.91M | $393.22M | $386.24M |
| Other Current Liabilities | $2.54B | $1.05B | $999.07M | $1.00B | $878.99M | $948.83M | $994.88M | $1.03B | $961.37M | $1.15B | $1.12B | $1.08B | $899.68M | $732.98M | $382.59M | $404.99M | $360.90M | $402.02M | $385.04M | $435.86M |
| Total Current Liabilities | $2.80B | $2.82B | $2.74B | $2.95B | $2.83B | $2.87B | $2.76B | $2.90B | $2.69B | $2.73B | $2.48B | $2.54B | $2.48B | $2.30B | $1.11B | $1.08B | $1.14B | $1.24B | $1.17B | $1.21B |
| Long Term Debt | $3.54B | $3.55B | $3.55B | $3.57B | $3.79B | $4.03B | $4.34B | $4.49B | $4.73B | $4.92B | $5.14B | $5.24B | $5.54B | $6.06B | $397.33M | $400.77M | $409.28M | $62.49M | $63.97M | $74.76M |
| Deferred Revenue Non-Current | $- | $- | $145.46M | $145.54M | $126.32M | $242.97M | $241.41M | $- | $- | $- | $- | $- | $735.00K | $760.00K | $13.26M | $14.47M | $838.00K | $13.85M | $13.35M | $15.28M |
| Deferred Tax Liabilities Non-Current | $812.49M | $818.33M | $843.63M | $869.52M | $899.10M | $883.89M | $934.21M | $957.02M | $988.59M | $974.34M | $1.02B | $1.06B | $1.09B | $1.23B | $13.55M | $9.86M | $10.17M | $12.82M | $10.46M | $11.36M |
| Other Non-Current Liabilities | $209.30M | $251.29M | $244.15M | $234.86M | $232.65M | $41.66M | $39.44M | $289.99M | $277.45M | $260.53M | $255.16M | $252.92M | $213.97M | $92.78M | $27.34M | $27.07M | $36.53M | $21.96M | $22.45M | $16.86M |
| Total Non-Current Liabilities | $4.56B | $4.62B | $4.64B | $4.67B | $4.92B | $5.20B | $5.55B | $5.73B | $6.00B | $6.16B | $6.41B | $6.55B | $6.84B | $7.38B | $451.48M | $452.17M | $446.65M | $111.13M | $110.24M | $118.25M |
| Other Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $7.35B | $7.44B | $7.38B | $7.62B | $7.75B | $8.07B | $8.31B | $8.63B | $8.69B | $8.89B | $8.89B | $9.09B | $9.32B | $9.69B | $1.56B | $1.53B | $1.59B | $1.35B | $1.28B | $1.33B |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock | $6.59M | $6.70M | $6.72M | $6.71M | $6.70M | $6.69M | $6.68M | $6.66M | $6.65M | $6.64M | $6.64M | $6.62M | $6.64M | $6.63M | $4.59M | $4.58M | $4.58M | $4.58M | $4.57M | $4.56M |
| Retained Earnings | $2.72B | $2.87B | $2.77B | $2.62B | $2.43B | $2.22B | $2.05B | $1.94B | $1.82B | $1.70B | $1.54B | $1.43B | $1.42B | $1.34B | $1.43B | $1.36B | $1.39B | $1.16B | $1.07B | $1.02B |
| Accumulated Other Comprehensive Income Loss | $-228.62M | $-108.88M | $-178.40M | $-165.30M | $-142.34M | $-190.19M | $-156.53M | $-159.90M | $-171.54M | $-291.90M | $-192.94M | $-126.75M | $-90.94M | $-79.20M | $-43.73M | $-54.97M | $-13.00M | $-66.50M | $-89.74M | $-98.95M |
| Other Total Stockholders Equity | $7.02B | $7.01B | $6.99B | $6.97B | $6.94B | $6.93B | $6.89B | $6.87B | $6.84B | $6.82B | $6.79B | $6.76B | $6.73B | $6.70B | $633.20M | $623.41M | $617.10M | $611.37M | $593.63M | $584.85M |
| Total Stockholders Equity | $9.52B | $9.77B | $9.59B | $9.43B | $9.24B | $8.96B | $8.80B | $8.65B | $8.50B | $8.24B | $8.15B | $8.07B | $8.07B | $7.97B | $2.03B | $1.93B | $1.88B | $1.71B | $1.58B | $1.51B |
| Total Equity | $9.52B | $9.77B | $9.59B | $9.43B | $9.24B | $8.96B | $8.80B | $8.65B | $8.50B | $8.24B | $8.15B | $8.07B | $8.07B | $7.97B | $2.03B | $1.93B | $1.88B | $1.71B | $1.58B | $1.51B |
| Total Liabilities and Stockholders Equity | $16.88B | $17.21B | $16.97B | $17.05B | $16.99B | $17.03B | $17.11B | $17.29B | $17.19B | $17.13B | $17.04B | $17.16B | $17.39B | $17.65B | $3.58B | $3.47B | $3.47B | $3.07B | $2.86B | $2.84B |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $16.88B | $17.21B | $16.97B | $17.05B | $16.99B | $17.03B | $17.11B | $17.29B | $17.19B | $17.13B | $17.04B | $17.16B | $17.39B | $17.65B | $3.58B | $3.47B | $3.47B | $3.07B | $2.86B | $2.84B |
| Total Investments | $57.95M | $53.72M | $137.83M | $140.31M | $48.76M | $43.74M | $36.95M | $33.70M | $34.34M | $29.64M | $29.33M | $29.30M | $26.68M | $27.53M | $27.77M | $24.60M | $22.03M | $19.54M | $13.05M | $11.77M |
| Total Debt | $3.57B | $3.58B | $3.58B | $3.65B | $3.94B | $4.16B | $4.44B | $4.62B | $4.79B | $4.98B | $5.19B | $5.30B | $5.60B | $6.12B | $397.33M | $400.77M | $433.61M | $412.42M | $413.80M | $424.49M |
| Net Debt | $3.03B | $2.88B | $3.08B | $3.25B | $3.56B | $3.85B | $4.17B | $4.34B | $4.50B | $4.37B | $4.58B | $4.74B | $4.84B | $5.11B | $-658.16M | $-541.68M | $-406.69M | $-295.58M | $-178.30M | $-57.88M |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $791.47M | $612.34M | $505.30M | $153.19M | $331.43M |
| Depreciation and Amortization | $512.03M | $585.95M | $569.51M | $314.99M | $95.07M |
| Deferred Income Tax | $- | $-85.40M | $-124.98M | $-60.62M | $50.75M |
| Stock Based Compensation | $45.87M | $55.67M | $70.52M | $133.84M | $26.27M |
| Change in Working Capital | $-18.77M | $-114.82M | $-550.22M | $135.00M | $114.71M |
| Accounts Receivables | $9.39M | $-78.58M | $-420.69M | $113.51M | $-175.04M |
| Inventory | $- | $- | $- | $- | $-1.63M |
| Accounts Payables | $- | $- | $- | $- | $26.49M |
| Other Working Capital | $-28.16M | $-36.24M | $-129.53M | $21.48M | $264.89M |
| Other Non Cash Items | $-43.96M | $107.30M | $93.18M | $152.75M | $-23.83M |
| Net Cash Provided by Operating Activities | $1.29B | $1.16B | $563.32M | $829.14M | $594.72M |
| Investments in Property Plant and Equipment | $-168.06M | $-140.69M | $-142.16M | $-93.75M | $-51.05M |
| Acquisitions Net | $-84.16M | $-71.77M | $-1.91M | $-5.92B | $-40.21M |
| Purchases of Investments | $- | $-16.81M | $-6.09M | $-4.06M | $-3.21M |
| Sales Maturities of Investments | $- | $2.62M | $2.39M | $497.00K | $47.90M |
| Other Investing Activities | $-14.57M | $- | $1.91M | $-10.00M | $42.24M |
| Net Cash Used for Investing Activities | $-266.79M | $-226.65M | $-145.87M | $-6.02B | $-46.58M |
| Debt Repayment | $-360.28M | $-895.00M | $-800.00M | $5.03B | $- |
| Common Stock Issued | $- | $50.96M | $- | $117.74M | $- |
| Common Stock Repurchased | $-500.00M | $- | $-99.98M | $- | $-175.00M |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $23.10M | $50.96M | $35.81M | $87.41M | $-33.33M |
| Net Cash Used Provided by Financing Activities | $-837.18M | $-844.04M | $-864.17M | $5.11B | $-235.02M |
| Effect of Forex Changes on Cash | $-22.00M | $-997.00K | $-16.72M | $-7.73M | $6.87M |
| Net Change in Cash | $160.68M | $89.33M | $-463.44M | $-88.09M | $320.00M |
| Cash at End of Period | $538.78M | $378.10M | $288.77M | $752.21M | $840.30M |
| Cash at Beginning of Period | $378.10M | $288.77M | $752.21M | $840.30M | $520.31M |
| Operating Cash Flow | $1.29B | $1.16B | $563.32M | $829.14M | $594.72M |
| Capital Expenditure | $-168.06M | $-140.69M | $-142.16M | $-93.75M | $-51.05M |
| Free Cash Flow | $1.12B | $1.02B | $421.15M | $735.39M | $543.67M |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $260.00M | $197.13M | $146.91M | $187.44M | $216.42M | $163.66M | $115.60M | $116.65M | $117.44M | $160.16M | $115.73M | $111.97M | $76.47M | $-94.27M | $73.86M | $97.12M | $101.23M | $91.64M | $47.76M | $92.33M |
| Depreciation and Amortization | $96.66M | $93.03M | $157.53M | $160.65M | $157.30M | $146.03M | $145.06M | $145.13M | $142.23M | $141.86M | $144.02M | $141.41M | $139.67M | $140.64M | $17.28M | $17.41M | $17.14M | $16.80M | $15.86M | $16.32M |
| Deferred Income Tax | $- | $-25.34M | $-25.85M | $-35.15M | $30.30M | $-55.31M | $-15.35M | $-43.82M | $1.64M | $-51.35M | $-40.56M | $-34.70M | $-34.08M | $-29.84M | $3.98M | $-664.00K | $-489.00K | $4.03M | $-905.00K | $-1.71M |
| Stock Based Compensation | $4.69M | $13.04M | $14.96M | $13.18M | $8.36M | $15.95M | $16.60M | $14.76M | $14.82M | $17.52M | $19.28M | $18.90M | $19.05M | $99.92M | $8.48M | $6.39M | $6.11M | $6.97M | $7.12M | $6.07M |
| Change in Working Capital | $-36.82M | $78.28M | $-126.07M | $-6.56M | $-2.25M | $56.86M | $-69.28M | $-98.80M | $-383.32M | $-72.93M | $-70.31M | $-23.66M | $44.04M | $102.28M | $2.79M | $-14.12M | $64.90M | $-13.49M | $35.38M | $22.05M |
| Accounts Receivables | $80.13M | $17.70M | $34.90M | $-122.98M | $47.40M | $-98.42M | $52.58M | $-93.26M | $-279.94M | $-99.73M | $-5.57M | $-35.46M | $-9.90M | $86.76M | $-15.37M | $52.02M | $-199.66M | $-33.55M | $55.30M | $2.87M |
| Inventory | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-34.95M | $-13.72M | $36.27M | $-30.75M | $-34.86M | $-2.14M |
| Accounts Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-10.33M | $-2.91M | $22.22M | $-4.10M | $9.27M | $-897.00K |
| Other Working Capital | $-116.95M | $60.59M | $-160.96M | $116.42M | $-49.65M | $155.28M | $-121.86M | $-5.54M | $-103.39M | $26.80M | $-64.74M | $11.80M | $53.94M | $15.52M | $63.44M | $-49.50M | $206.08M | $54.90M | $5.67M | $22.23M |
| Other Non Cash Items | $13.79M | $46.54M | $344.05M | $464.97M | $19.03M | $14.32M | $11.26M | $41.59M | $47.77M | $18.53M | $13.89M | $13.00M | $44.67M | $80.25M | $22.05M | $5.78M | $6.52M | $6.01M | $12.68M | $7.69M |
| Net Cash Provided by Operating Activities | $338.31M | $402.67M | $216.41M | $327.08M | $429.17M | $341.51M | $203.88M | $175.50M | $-59.43M | $213.78M | $182.05M | $226.92M | $289.82M | $298.97M | $128.43M | $111.92M | $195.42M | $111.97M | $117.89M | $142.76M |
| Investments in Property Plant and Equipment | $-61.29M | $-43.33M | $-36.03M | $-27.15M | $-51.38M | $-29.10M | $-32.14M | $-26.74M | $-57.02M | $-37.30M | $-28.21M | $-19.63M | $-47.68M | $-24.41M | $-12.95M | $-8.70M | $-23.03M | $-6.87M | $-9.85M | $-11.31M |
| Acquisitions Net | $1.47M | $-77.80M | $31.30K | $-7.83M | $-66.25M | $2.29K | $-5.14M | $1.30M | $-2.71M | $- | $- | $- | $99.77M | $-5.91B | $-2.45M | $- | $-10.17M | $-3.01M | $-34.00K | $-37.16M |
| Purchases of Investments | $- | $-4.51M | $-211.53K | $-5.39M | $-3.96M | $-7.53M | $-3.38M | $-1.78M | $-4.25M | $-1.04M | $- | $- | $-1.81M | $-472.00K | $-1.17M | $-599.00K | $-475.00K | $-1.46M | $-1.09M | $-187.00K |
| Sales Maturities of Investments | $- | $1.36M | $2.31M | $1.00M | $980.38K | $1.13M | $3.46K | $482.00K | $2.39M | $- | $-96.00K | $96.00K | $480.00K | $16.73K | $- | $- | $- | $- | $-1.00K | $47.90M |
| Other Investing Activities | $-9.06M | $-61.62K | $2.09M | $-4.38M | $-1 | $-2.29K | $33.14K | $-1.30M | $2.71M | $-1.04M | $-799.00K | $96.00K | $-10.00M | $17.00K | $-3.62M | $-599.00K | $-475.00K | $-3.91M | $-1.09M | $47.72M |
| Net Cash Used for Investing Activities | $-68.88M | $-124.34M | $-33.91M | $-39.37M | $-120.61M | $-35.50M | $-40.61M | $-28.04M | $-58.88M | $-38.35M | $-29.10M | $-19.54M | $-59.02M | $-5.94B | $-16.57M | $-9.30M | $-23.50M | $-11.34M | $-10.97M | $-758.00K |
| Debt Repayment | $-7.44M | $-7.44M | $-64.02M | $-280.00M | $-261.08M | $-275.00M | $-180.00M | $-170.00M | $-200.00M | $-200.00M | $-125.00M | $-300.00M | $-500.00M | $5.53B | $- | $- | $- | $- | $- | $- |
| Common Stock Issued | $- | $9.98M | $-6.39M | $16.30M | $13.94M | $16.44M | $7.38M | $12.94M | $- | $12.54M | $7.26M | $- | $12.29M | $101.39M | $172.08K | $- | $- | $- | $- | $- |
| Common Stock Repurchased | $-400.00M | $-101.11M | $- | $- | $- | $- | $- | $- | $- | $3.21M | $2.57M | $-99.98M | $- | $- | $- | $- | $- | $- | $- | $-175.00M |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $3.48M | $-90.34M | $-7.73M | $16.30M | $13.94M | $16.34M | $7.23M | $12.94M | $2.22M | $13.83M | $32.65M | $7.47M | $14.54M | $72.70M | $172.00K | $- | $-45.53M | $10.88M | $591.00K | $724.00K |
| Net Cash Used Provided by Financing Activities | $-403.96M | $-97.78M | $-70.41M | $-263.70M | $-247.14M | $-258.67M | $-172.77M | $-157.06M | $-193.14M | $-186.17M | $-92.35M | $-392.51M | $-485.46M | $5.60B | $172.00K | $-5.00K | $-45.53M | $10.88M | $591.00K | $-174.28M |
| Effect of Forex Changes on Cash | $-22.20M | $8.40M | $-2.17M | $-6.03M | $2.96M | $-4.46M | $-206.00K | $718.00K | $-8.95M | $4.98M | $-4.78M | $-7.98M | $-1.65M | $-6.62M | $1.01M | $-467.00K | $5.92M | $4.39M | $2.22M | $-5.66M |
| Net Change in Cash | $-156.72M | $188.95M | $110.47M | $17.98M | $65.04M | $42.89M | $-9.70M | $-8.89M | $-320.39M | $-5.76M | $55.82M | $-193.12M | $-256.31M | $-46.97M | $113.04M | $102.15M | $132.31M | $115.89M | $109.73M | $-37.94M |
| Cash at End of Period | $538.78M | $695.51M | $506.55M | $396.08M | $378.10M | $313.06M | $270.18M | $279.88M | $288.77M | $609.16M | $614.92M | $559.10M | $752.21M | $1.01B | $1.06B | $942.46M | $840.30M | $708.00M | $592.10M | $482.37M |
| Cash at Beginning of Period | $695.51M | $506.55M | $396.08M | $378.10M | $313.06M | $270.18M | $279.88M | $288.77M | $609.16M | $614.92M | $559.10M | $752.21M | $1.01B | $1.06B | $942.46M | $840.30M | $708.00M | $592.10M | $482.37M | $520.31M |
| Operating Cash Flow | $338.31M | $402.67M | $216.41M | $327.08M | $429.17M | $341.51M | $203.88M | $175.50M | $-59.43M | $213.78M | $182.05M | $226.92M | $289.82M | $298.97M | $128.43M | $111.92M | $195.42M | $111.97M | $117.89M | $142.76M |
| Capital Expenditure | $-61.29M | $-43.33M | $-36.03M | $-27.15M | $-51.38M | $-29.10M | $-32.14M | $-26.74M | $-57.02M | $-37.30M | $-28.21M | $-19.63M | $-47.68M | $-24.41M | $-12.95M | $-8.70M | $-23.03M | $-6.87M | $-9.85M | $-11.31M |
| Free Cash Flow | $277.03M | $359.34M | $180.37M | $299.92M | $377.79M | $312.42M | $171.75M | $148.76M | $-116.44M | $176.47M | $153.84M | $207.28M | $242.13M | $274.56M | $115.48M | $103.22M | $172.39M | $105.10M | $108.04M | $131.45M |
ICON Public Dividends
Explore ICON Public's dividend history, including dividend yield, payout ratio, and historical payments.
ICON Public News
Read the latest news about ICON Public, including recent articles, headlines, and updates.
Investors who Lost Money on ICON Public Limited Company (ICLR) Should Contact Levi & Korsinsky about Pending Class Action - ICLR
NEW YORK, NY / ACCESS Newswire / March 21, 2025 / If you suffered a loss on your ICON Public Limited Company (NASDAQ:ICLR) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/icon-public-limited-company-lawsuit-submission-form?prid=137915&wire=1 or contact Joseph E. Levi, Esq.
ROSEN, LEADING INVESTOR COUNSEL, Encourages ICON plc Investors to Secure Counsel Before Important Deadline in Securities Class Action - ICLR
NEW YORK CITY, NY / ACCESS Newswire / March 21, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of ordinary shares of ICON plc (NASDAQ:ICLR) between July 27, 2023 and October 23, 2024, both dates inclusive (the "Class Period"), of the important April 11, 2025 lead plaintiff deadline. SO WHAT: If you purchased ICON ordinary shares during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Class Action Filed Against ICON Public Limited Company (ICLR) - April 11, 2025 Deadline to Join – Contact Levi & Korsinsky
NEW YORK, NY / ACCESS Newswire / March 21, 2025 / If you suffered a loss on your ICON Public Limited Company (NASDAQ:ICLR) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/icon-public-limited-company-lawsuit-submission-form?prid=137901&wire=1 or contact Joseph E. Levi, Esq.
ICLR CLASS ACTION ALERT: Kessler Topaz Meltzer & Check, LLP Reminds ICON Public Limited Company Shareholders of Securities Fraud Class Action Lawsuit
RADNOR, Pa., March 21, 2025 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Eastern District of New York against ICON Public Limited Company (“ICON”) (NASDAQ: ICLR) on behalf of all purchasers of ICON ordinary shares between July 27, 2023 and October 23, 2024, inclusive (the “Class Period”). The lead plaintiff deadline is April 11, 2025.
ICON plc (ICLR) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
LOS ANGELES , March 21, 2025 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to ICON plc ("ICON" or the "Company") (NASDAQ: ICLR) have opportunity to lead the securities fraud class action lawsuit.
Investors in ICON Public Limited Company Should Contact Levi & Korsinsky Before April 11, 2025 to Discuss Your Rights - ICLR
NEW YORK, NY / ACCESS Newswire / March 21, 2025 / If you suffered a loss on your ICON Public Limited Company (NASDAQ:ICLR) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/icon-public-limited-company-lawsuit-submission-form?prid=137814&wire=1 or contact Joseph E. Levi, Esq.
Shareholders That Lost Money on ICON Public Limited Company(ICLR) Should Contact Levi & Korsinsky about Pending Class Action - ICLR
NEW YORK, NY / ACCESS Newswire / March 21, 2025 / If you suffered a loss on your ICON Public Limited Company (NASDAQ:ICLR) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/icon-public-limited-company-lawsuit-submission-form?prid=137796&wire=1 or contact Joseph E. Levi, Esq.
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ICON Public Limited Company of Class Action Lawsuit and Upcoming Deadlines - ICLR
NEW YORK CITY, NY / ACCESS Newswire / March 21, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against ICON Public Limited Company ("Icon" or the "Company") (NASDAQ: ICLR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
Levi & Korsinsky Notifies ICON Public Limited Company Investors of a Class Action Lawsuit and Upcoming Deadline - ICLR
NEW YORK, NY / ACCESS Newswire / March 21, 2025 / If you suffered a loss on your ICON Public Limited Company (NASDAQ:ICLR) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/icon-public-limited-company-lawsuit-submission-form?prid=137674&wire=1 or contact Joseph E. Levi, Esq.
ICLR Investor Alert: A Securities Fraud Class Action Lawsuit Has Been Filed Against ICON Public Limited Company (ICLR)
RADNOR, Pa. , March 21, 2025 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against ICON Public Limited Company ("ICON") (NASDAQ: ICLR) on behalf of all purchasers of ICON ordinary shares between July 27, 2023 and October 23, 2024, inclusive (the "Class Period").
Lost Money on ICON Public Limited Company(ICLR)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
NEW YORK, NY / ACCESS Newswire / March 21, 2025 / If you suffered a loss on your ICON Public Limited Company (NASDAQ:ICLR) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/icon-public-limited-company-lawsuit-submission-form?prid=137665&wire=1 or contact Joseph E. Levi, Esq.
ICLR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ICON PLC Investors with Losses Have Opportunity to Lead Class Action Lawsuit!
NEW YORK, NY / ACCESS Newswire / March 21, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against ICON PLC ("ICON" or "the Company") (NASDAQ:ICLR) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired ICON securities between July 27, 2023 and October 23, 2024, both dates inclusive (the "Class Period").
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 11, 2025 in ICON Lawsuit - ICLR
NEW YORK , March 21, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in ICON Public Limited Company ("ICON " or the "Company") (NASDAQ: ICLR) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of ICON investors who were adversely affected by alleged securities fraud between July 27, 2023 and October 23, 2024.
Shareholders that lost money on ICON Public Limited Company(ICLR) Urged to Join Class Action – Contact Levi & Korsinsky to Learn More
NEW YORK, NY / ACCESS Newswire / March 20, 2025 / If you suffered a loss on your ICON Public Limited Company (NASDAQ:ICLR) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/icon-public-limited-company-lawsuit-submission-form?prid=137623&wire=1 or contact Joseph E. Levi, Esq.
ICON SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against ICON plc - ICLR
NEW YORK CITY, NY AND NEW ORLEANS, LA / ACCESS Newswire / March 20, 2025 / Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until April 11, 2025 to file lead plaintiff applications in a securities class action lawsuit against ICON plc (the "Company") (NasdaqGS:ICLR), if they purchased the Company's shares between July 27, 2023 and October 23, 2024, inclusive (the "Class Period").
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 11, 2025 in ICON Public Limited Company Lawsuit - ICLR
NEW YORK, NY / ACCESS Newswire / March 20, 2025 / If you suffered a loss on your ICON Public Limited Company (NASDAQ:ICLR) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/icon-public-limited-company-lawsuit-submission-form?prid=137613&wire=1 or contact Joseph E. Levi, Esq.
ICLR LAWSUIT ALERT: Levi & Korsinsky Notifies ICON Public Limited Company Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK, NY / ACCESS Newswire / March 20, 2025 / If you suffered a loss on your ICON Public Limited Company (NASDAQ:ICLR) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/icon-public-limited-company-lawsuit-submission-form?prid=137566&wire=1 or contact Joseph E. Levi, Esq.
ROSEN, NATIONAL TRIAL LAWYERS, Encourages ICON plc Investors to Secure Counsel Before Important Deadline in Securities Class Action – ICLR
NEW YORK, March 20, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of ordinary shares of ICON plc (NASDAQ: ICLR) between July 27, 2023 and October 23, 2024, both dates inclusive (the “Class Period”), of the important April 11, 2025 lead plaintiff deadline.
ICON Public Limited Company Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before April 11, 2025 to Discuss Your Rights - ICLR
NEW YORK, NY / ACCESS Newswire / March 20, 2025 / If you suffered a loss on your ICON Public Limited Company (NASDAQ:ICLR) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/icon-public-limited-company-lawsuit-submission-form?prid=137533&wire=1 or contact Joseph E. Levi, Esq.
ICON SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against ICON plc - ICLR
NEW ORLEANS, March 20, 2025 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until April 11, 2025 to file lead plaintiff applications in a securities class action lawsuit against ICON plc (the “Company”) (NasdaqGS: ICLR), if they purchased the Company's shares between July 27, 2023 and October 23, 2024, inclusive (the “Class Period”). This action is pending in the United States District Court for the Eastern District of New York.
Shareholders of ICON Public Limited Company Should Contact Levi & Korsinsky Before April 11, 2025 to Discuss Your Rights - ICLR
NEW YORK, NY / ACCESS Newswire / March 20, 2025 / If you suffered a loss on your ICON Public Limited Company (NASDAQ:ICLR) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/icon-public-limited-company-lawsuit-submission-form?prid=137338&wire=1 or contact Joseph E. Levi, Esq.
ICLR SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ICON PLC Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
NEW YORK, NY / ACCESS Newswire / March 20, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against ICON PLC ("ICON" or "the Company") (NASDAQ:ICLR) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired ICON securities between July 27, 2023 and October 23, 2024, both dates inclusive (the "Class Period").
ICON Public Limited Company Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before April 11, 2025 to Discuss Your Rights - ICLR
NEW YORK , March 20, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of ICON Public Limited Company (NASDAQ: ICLR). Shareholders who purchased shares of ICLR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
ICON Becomes the First Large Clinical Research Organization to Fully Integrate Medidata Clinical Data Studio, Streamlining Data Management and Review
NEW YORK--(BUSINESS WIRE)--Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, today announced that ICON plc, (NASDAQ: ICLR) a world-leading clinical research organization (CRO) powered by healthcare intelligence, will immediately begin utilizing Medidata Clinical Data Studio on its studies, differentiating ICON as the first large CRO to fully infuse this technology into its clinical workflows. The integration of Clinical Data Stud.
Lost Money on ICON Public Limited Company (ICLR)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
NEW YORK, NY / ACCESS Newswire / March 19, 2025 / If you suffered a loss on your ICON Public Limited Company (NASDAQ:ICLR) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/icon-public-limited-company-lawsuit-submission-form?prid=137291&wire=1 or contact Joseph E. Levi, Esq.
ICLR Purchasers Have Opportunity to Lead ICON plc Securities Fraud Lawsuit
NEW YORK , March 19, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of ordinary shares of ICON plc (NASDAQ: ICLR) between July 27, 2023 and October 23, 2024, both dates inclusive (the "Class Period"), of the important April 11, 2025 lead plaintiff deadline. So what: If you purchased ICON ordinary shares during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for ICLR.